Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
- 2021年03月12日 14:00:00
- テクノロジー
- JCN Newswire
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19.
Yvonne Lungershausen, CEO, Avance Clinical said:
"As the CRO for this important study, we congratulate Atossa Therapeutics on these impressive safety and tolerability clinical results. Atossa Therapeutics have tapped the full scope of our CRO services including ClinicReady, our scientific and medical affairs specialist team. Australian clinical trials are recognized globally for their speed and accuracy and the fact that the clinical data is accepted by all major regulatory authorities including the FDA. Increasingly our clients are also tapping the generous 43.5% Australian Government rebate to support their clinical research."
According to Atossa Therapeutics:
Atossa Therapeutics today announced final results from its Phase 1 double-blinded, randomized, placebo-controlled clinical study using Atossa's proprietary drug candidate AT-301 administered by nasal spray. AT-301 was considered to be safe and well tolerated in healthy male and female participants in this study at two different dose levels over 14 days. AT-301 is being developed for at home use for patients recently diagnosed with COVID-19. There are currently no FDA-approved therapies to treat COVID-19 at home.
Final analysis of the data from the study indicates that there were no serious adverse events, no discontinuations, no bronchospasms, and only one subject of the 32 subjects in the study experienced adverse events that were considered moderate in severity and all other adverse events were considered mild.
Atossa's assessment is that AT-301 nasal spray was safe and well tolerated in this study. The most common treatment-related adverse events observed with AT-301 treatment with either single or multiple doses were nasal discomfort and sneezing.
"The results from this study are very encouraging and we look forward to quickly commencing the next study of AT-301,"commented Steven Quay, M.D., Ph.D., Atossa's President and CEO.
Atossa believes that AT-301 nasal spray will play an important role alongside the traditional vaccines now being deployed, particularly as it becomes clear that it will take months or years for vaccines to be administered around the world.
The Phase 1 study was a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects who were divided into two study groups.
Part A consists of two single-dose cohorts receiving either active therapy, AT-301B, or the placebo comparator AT-301A at two different doses. Part B was a multiple dose arm with cohorts receiving either AT-301A or AT-301B for 14 days at two different doses.
The primary objectives of the study were to evaluate the safety and tolerability of single and multiple doses of AT-301 administered via nasal instillation to healthy volunteers. Secondary objectives were to assess the incidence and severity of local irritation and bronchospasm following administration of AT-301 via nasal instillation.
The study was being conducted in Australia.
See full announcement here. https://tinyurl.com/6fchfvh2
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.
About Avance Clinical
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. Visit http://www.avancecro.com for more information.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5-6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
Media Contact:
Chris Thompson
media@avancecro.com
Copyright 2021 JCN Newswire. All rights reserved. www.jcnnewswire.com
リサイクルショップで大量のスクール水着が販売、あっという間に完売したと話題に
乃木坂山下美月卒コン、3期生が思い伝え涙「器用に見えて不器用で」「『くぼした』幸せでした」
乃木坂山下美月、涙の東京ドーム卒コン「生まれ変わっても皆さんと会いたい」2日間で10万人動員
奥田民生「松本の代理です!」ダウンタウン浜田誕生日祝う 浜田は松本作詞「チキンライス」熱唱
名古屋のマンションに乳児とみられる2遺体 契約者の知人女性を聴取
【ヤクルト】左膝の前十字靱帯と半月板損傷の塩見泰隆は「相当落ち込んでいた」と高津監督
腎臓に腫瘍の68歳大友康平復帰ライブ「俺は不死身のロッケンローラー!」秋のライブ開催も発表
【巨人】阿部監督、1日で首位陥落も悲壮感全くなく「いい1週間だった、来週また切り替えて」
【阪神】巨人敗戦し一夜で首位奪還 前日7点差逆転負けも先発才木浩人の完封劇で返り咲き
【巨人】岡本和真、今季初2戦連続弾「出たにこしたことはない」不調脱し2戦3発と量産モード
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
73歳神田正輝「旅サラダ」生放送で“12歳下俳優”から呼び捨てされ激論
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
曙と熱愛した相原勇(52)の現在が衝撃的すぎると話題に
55歳森口博子「だっちゅーの」鮮やかビキニ姿披露にX歓喜「破壊力ハンパない」「スゴすぎ」
「ふてほど」25歳女優“薔薇ブラ”でポロリ寸前?過激衣装に「見えちゃう」「刺激強すぎ」
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
大物炎上系ユーチューバー”衝撃の預金残高”公開「すげぇ」「エグい」驚きの声
水原一平容疑者 最高刑「懲役33年」トレンド入り 「人生詰んだ」「稀代の詐欺師」の声
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
深夜のファミリーマート徘徊、必ず入っている「フエラムネのミニチュアおもちゃ付」を探し求めた結果……
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
完全にダマされた! 『ラヴィット!』あのちゃん“事故レベル”大暴走は『水ダウ』遠隔操作のしわざだった ネットも納得
ガーシー、またも綾野剛の暴露写真でネット歓喜「この写真見て笑っちゃう」
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
小澤征悦と再婚した桑子真帆アナ(34)黒い過去が流出、衝撃の過去にネット騒然
ガーシー、佐野ひなこの暴露を示唆でネット騒然「ファンだったのに」
ガーシーが綾野剛のLINE公開でネット騒然「ショック」「すごいエンタメ」
リサイクルショップで大量のスクール水着が販売、あっという間に完売したと話題に
乃木坂山下美月卒コン、3期生が思い伝え涙「器用に見えて不器用で」「『くぼした』幸せでした」
乃木坂山下美月、涙の東京ドーム卒コン「生まれ変わっても皆さんと会いたい」2日間で10万人動員
奥田民生「松本の代理です!」ダウンタウン浜田誕生日祝う 浜田は松本作詞「チキンライス」熱唱
名古屋のマンションに乳児とみられる2遺体 契約者の知人女性を聴取
【ヤクルト】左膝の前十字靱帯と半月板損傷の塩見泰隆は「相当落ち込んでいた」と高津監督
腎臓に腫瘍の68歳大友康平復帰ライブ「俺は不死身のロッケンローラー!」秋のライブ開催も発表
【阪神】巨人敗戦し一夜で首位奪還 前日7点差逆転負けも先発才木浩人の完封劇で返り咲き
【巨人】阿部監督、1日で首位陥落も悲壮感全くなく「いい1週間だった、来週また切り替えて」
【巨人】岡本和真、今季初2戦連続弾「出たにこしたことはない」不調脱し2戦3発と量産モード